Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience (NASDAQ: TWST) has announced a -time offer for academic customers globally, providing Express Genes orders with expedited shipping in as few as four days at no additional cost. This initiative aims to support research institutions facing budget constraints while maintaining scientific progress.
The Express Genes offering includes:
- Gene lengths ranging from 0.3kb to 5.0kb
- NGS sequence verification with 100% accuracy
- Flexibility in order volume
- Options for cloning into catalog or custom vectors
- Multiple delivery format options including tubes and plates
This move represents Twist's commitment to supporting academic research by eliminating premium charges for rapid turnaround times, helping institutions maximize their research budgets.
Twist Bioscience (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, has announced its executives' participation in upcoming investor conferences.
The schedule includes:
- Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, at the TD Cowen 45th Annual Health Care Conference on March 4 in Boston (fireside chat at 1:50 pm ET)
- Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, at the Leerink Global Biopharma Conference 2025 on March 11 in Miami (fireside chat at 9:20 am ET)
- Patrick Finn and Adam Laponis at the Barclays Global Healthcare Conference 2025 on March 12 in Miami (fireside chat at 8:30 am ET)
All fireside chats will be webcast live through the investor relations section of the company's website and archived for 30 days after the events.
Twist Bioscience (NASDAQ: TWST) has announced the granting of 123,024 equity awards to 32 newly hired employees as employment inducements. The awards consist of 72,394 restricted stock units (RSUs) and up to 50,630 performance stock units (PSUs).
The RSUs will vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs will vest based on performance metrics set by the Board's Compensation Committee, achievable by the end of fiscal 2027 at 50%-140% of target. Both are subject to continued employment.
These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new hires or those returning after non-employment periods.
Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company in the healthcare sector, has announced its financial results for the first quarter of fiscal 2025, which ended December 31, 2024. The company has scheduled a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update.
Participants interested in joining via telephone must register through the company's Investor Relations website. Detailed earnings report and investor presentation are available on the Events and Presentations page of Twist Bioscience's website. A webcast replay will be accessible for two weeks following the call.
Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2025 first quarter financial results for the period ended December 31, 2024, before market opening on February 3, 2025. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time on the same day.
Participants interested in joining via telephone must pre-register through the company's Investor Relations website. The financial results press release will be available on the company's website in the Investor Relations section. A webcast replay will be accessible for two weeks following the call.
Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company, has announced that CEO and co-founder Emily M. Leproust, Ph.D. will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 5:15 p.m. Pacific Time in San Francisco, California.
The event will be accessible via webcast through the company's investor relations website's 'Investor Calendar' section. Following the live presentation, a replay will remain available for 30 days.
Twist Bioscience (NASDAQ: TWST) announced its financial results for Q4 and full year fiscal 2024 ended September 30, 2024. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can access detailed earnings reports and investor presentations through the company's website. Those joining via telephone must register in advance to receive dial-in information.
Twist Bioscience (NASDAQ: TWST), a synthetic DNA manufacturer, announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO and co-founder Emily M. Leproust, Ph.D., along with CFO Adam Laponis, will engage in a fireside chat on December 3, 2024, at 10:00 a.m. Eastern Time in Coral Gables, Florida. The event will be accessible via live webcast through the company's investor relations website, with a replay available for 30 days after the presentation.
Twist Bioscience (NASDAQ: TWST) has announced new equity awards as employment inducements under Nasdaq Rule 5635(c)(4). The company granted 110,300 restricted stock units (RSUs) to 43 new employees and up to 37,500 performance stock units (PSUs) to VP Colby Souders. The RSUs vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs vest based on performance metrics for FY2024-2026, with potential earnings of 80%-150% of target, subject to continued employment.
Twist Bioscience (NASDAQ: TWST) has launched the FlexPrep™ Ultra-High Throughput Library Preparation Kit, featuring proprietary Normalization by Ligation™ technology. The kit enables processing of thousands of samples at low cost, eliminating the need for upfront sample quantitation and allowing early sample pooling. Researchers can run up to 1,152 samples in a single 96-well plate, reducing consumables by 12x and pipette tips usage from 17,000 to under 4,000. The company is collaborating with Gencove to provide genomic analysis software, offering an end-to-end workflow solution for agricultural and population genomics applications.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
